SYNGENE INTERNATIONAL: CO HAS RETURNED TO GROWTH IN THIS QUARTER AND FORESEES THE GROWTH MOMENTUM CONTINUING INTO THE FOURTH QUARTER OF THE FINANCIAL YEAR || DESPITE THE CHALLENGES FACED IN THE FIRST HALF OF THE YEAR, THE CO EXPECTS TO CLOSE THE FULL YEAR WITH SINGLE-DIGIT REVENUE GROWTH AND A FLAT PAT || EBITDA GUIDANCE REMAINS UNCHANGED - INVESTOR PRESENTATION

 23 Jan 2025 10:46 PM

SYNGENE INTERNATIONAL: CO HAS RETURNED TO GROWTH IN THIS QUARTER AND FORESEES THE GROWTH MOMENTUM CONTINUING INTO THE FOURTH QUARTER OF THE FINANCIAL YEAR || DESPITE THE CHALLENGES FACED IN THE FIRST HALF OF THE YEAR, THE CO EXPECTS TO CLOSE THE FULL YEAR WITH SINGLE-DIGIT REVENUE GROWTH AND A FLAT PAT || EBITDA GUIDANCE REMAINS UNCHANGED - INVESTOR PRESENTATION

SYNGENE INTERNATIONAL: CO SAYS DISCOVERY SERVICES CONVERTED INITIAL PILOT PROJECTS INTO FULL-FLEDGED CONTRACTS, WHICH SHOULD CONTRIBUTE TO GROWTH INTO NEXT YEAR - INVESTOR PRESENTATION

 23 Jan 2025 08:10 PM

SYNGENE INTERNATIONAL: CO SAYS DISCOVERY SERVICES CONVERTED INITIAL PILOT PROJECTS INTO FULL-FLEDGED CONTRACTS, WHICH SHOULD CONTRIBUTE TO GROWTH INTO NEXT YEAR - INVESTOR PRESENTATION

Syngene Q3 Results: Net profit rose 18% YoY to Rs 131 crore

 23 Jan 2025 05:57 PM

Syngene reported 18% YoY growth in Q3FY25 net profit. Revenue rose 11% YoY. EBITDA margin improved to 31.4%. Company expects single-digit revenue growth and flat profit after tax for FY25.

SYNGENE INTERNATIONAL: Q3 REVENUE 9.4B RUPEES VS 8.53B (YOY)

 23 Jan 2025 03:02 PM

SYNGENE INTERNATIONAL: Q3 REVENUE 9.4B RUPEES VS 8.53B (YOY)

SYNGENE INTERNATIONAL: Q3 EBITDA 2.8B RUPEES VS 2.3B (YOY) || Q3 EBITDA MARGIN 30.05% VS 27.12% (YOY)

 23 Jan 2025 03:02 PM

SYNGENE INTERNATIONAL: Q3 EBITDA 2.8B RUPEES VS 2.3B (YOY) || Q3 EBITDA MARGIN 30.05% VS 27.12% (YOY)

SYNGENE INTERNATIONAL: Q3 CONS NET PROFIT 1.3B RUPEES VS 1.1B (YOY)

 23 Jan 2025 03:01 PM

SYNGENE INTERNATIONAL: Q3 CONS NET PROFIT 1.3B RUPEES VS 1.1B (YOY)

BIOCON: CO SELLS 8M EQUITY SHARES OF SYNGENE INTERNATIONAL THROUGH BLOCK DEAL || SHAREHOLDING IN SYNGENE NOW AT 52.46%; CO RECEIVES APPROXIMATELY 6.86B RUPEES FROM SALE

 10 Dec 2024 05:03 PM

BIOCON: CO SELLS 8M EQUITY SHARES OF SYNGENE INTERNATIONAL THROUGH BLOCK DEAL || SHAREHOLDING IN SYNGENE NOW AT 52.46%; CO RECEIVES APPROXIMATELY 6.86B RUPEES FROM SALE

Pharma stocks catch a cold as US softens stance on Biosecure Act

 10 Dec 2024 05:39 AM

Shares of Syngene International dropped 5.7%, Piramal Pharma fell 4.2%, Lauras Labs and Neuland Laboratories declined 3% and Divi's Laboratories fell 2.8% on Monday. The BSE 500 was down 0.1%.

SYNGENE: BLOCK DEAL ALERT - BIOCON TO SELL UPTO 2% STAKE IN CO VIA BLOCK DEALS || TOTAL DEAL SIZE AT $80 MN OR RS 640 CRORES || KOTAK SEC BANKER TO BLOCK DEAL || BLOCK DEAL FLOOR PRICE AT RS 825, UPTO 5% DISCOUNT LIKELY || DEAL SIZE OF 80 LAKH SHARES AS PER TERMS - CNBC AWAAZ, CITING SOURCES

 09 Dec 2024 06:52 PM

SYNGENE: BLOCK DEAL ALERT - BIOCON TO SELL UPTO 2% STAKE IN CO VIA BLOCK DEALS || TOTAL DEAL SIZE AT $80 MN OR RS 640 CRORES || KOTAK SEC BANKER TO BLOCK DEAL || BLOCK DEAL FLOOR PRICE AT RS 825, UPTO 5% DISCOUNT LIKELY || DEAL SIZE OF 80 LAKH SHARES AS PER TERMS - CNBC AWAAZ, CITING SOURCES

SYNGENE: SETBACK FOR INDIAN CDMO SPACE || FATE OF THE US BIOSECURE ACT WITH EACH PASSING DAY THE PROBABILITY OF BIOSECURE ACT PASSING BY THE US SENATE IS REDUCING - SALES NOTE

 04 Dec 2024 09:50 AM

SYNGENE: SETBACK FOR INDIAN CDMO SPACE || FATE OF THE US BIOSECURE ACT WITH EACH PASSING DAY THE PROBABILITY OF BIOSECURE ACT PASSING BY THE US SENATE IS REDUCING - SALES NOTE